An observational study in The Aim of This Study is to Follow up Short Term "3-6 Months"& Mid Term" 6-12months "Outcomes of Vascular Access" Native and Synthetic "in ESRD Pediatrics, sponsored by Alaa Gameil Abd El-salam Hussien. Active, not recruiting at 1 site in Egypt. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Alaa Gameil Abd El-salam Hussien · Observational
Vascular access in the pediatric hemodialysis patients is a challenging,but necessary. It requires proper advance planning to assure that the best permanent access is placeds long life span. It is imperative to have a long-term vision to decrease morbidity in this unique patient population.
Recent data indicate that the incidence of end stage renal disease (ESRD) in pediatrics has increased over the past two decades[1]. Hemodialysis continues to be the most frequently utilized modality for renal replacement therapy in pediatric ESRD patients One of the most challenging aspects of kidney replacement therapy in children is the creation and maintenance of a functioning vascular access to provide adequate blood flow for uremic solute removal during haemodialysis, whilst minimizing the risk of systemic infections and preserving vascular access choices for future dialysis. There are three common forms of vascularaccess: tunnelled cuffed lines placed in a central vein, arteriovenous fistulas and arteriovenous grafts using prosthetic or biological material. arterio-venous fistula"nativevascularaccesses" are the preferred vascularaccess for children on hemodialysis. Compared with a CVL, a functional artirio-venous fistula is associated with better dialysis adequacy,significantly lowering complication rates and access failure.However, CVLs remain the most frequently used vascular access in all paediatric age groups, despite international recommendations[1-4] pediatrics with ESRD from age (1-6years) start with peritoneal dialysis, and then from age (6-18years) start to use hemodialysis The 'ideal artrio-venous fistula ' is made distally in the non-dominant arm,e.g. a radiocephalic AVF, and suitable vessels are veins>2 mm and arteries > 1 mm [5,6]. Apart from vessel size,many other factors should be considered when deciding which access to create e.g. psychological preparation of the child/parent, surgical expertise, child size/weight, quality of veins,cosmetic concerns for the teenager and hand dominance for the child who wishes to self-cannulate. Maintaining the confidence of the child, parent and dialysis nursing team is vitalwhen forming the access.
thisisdone by the aid ofduplexultrasound to assess size of vein,sizeofartery,patencyofcentralvenoussystem physical examination to assess blood pressure it's important to maintain blood pressure >120,\<160 to allow patency of vascular access.All thisisimportant tominimize/avoid the prolonged use of CVCs due to risks ofinfection and the need for vessel preservation. we need to use good clinical judgment when choosing the appropriate vascular access in each patient.
possible complications that can occur affecting patency of vascular access include:
Stenosis(Stenosis is a common complication which may affect the function of an AVF, it is the main cause of arterio-venousfistula thrombosis and failure) [7]
. Factors that predispose to the formation of venous neo-intimal hyperplasia and stenoses include the Following: surgical injury, recurrent traumatic cannulaltion (leading to defective vascularre modelling), high blood flow inducing endothelial cell dysfunction andshear stress. Stenoses commonly present clinically with inadequate pump speed, poor dialysis adequacy or a prolonged post-dialysis bleeding time. Physical examination should be correlated with a Doppler ultrasound assessment to investigate any clinically significant stenosis. In the absence of any clinical issues, an arterio-venous fistula stenosis is considered significant if there is >20% reduction from baseline volume
Haemodynamic issues High-output cardiac failure is occasionally seen in adults but is uncommon in children and is managed with arterio-venous fistula volume flow reduction . Steal syndrome ] occurs when a significant proportion of cardiac output is diverted from the distalcapillary bed by the proximal arterio-venous fistula, causing distal ischemia [11,12]. This is also rare but may require surgical revision to preserve the access and alleviate the distal ischaemia.
This is the only study on the registry with Alaa Gameil Abd El-salam Hussien as lead sponsor.
Counted across the registry records on this site, refreshed daily.
All patients fulfilling the inclusion and exclusion criteria will be included in this study with time frame 1year
Exclusion Criteria:
1)Children with ESRD contraindicated for vascular intervention including: Children with resistance hyper-tention Children with medical history of bleeding tendency Children with hyper-coagulable state 2)children with duplex criteria including: vein fibrotic "\<2mm" artery\<1mm occluded central veins 3)Children's parents not compliance to follow up
-
The aim of this study is to follow up Short term "3-6 months"& Mid term" 6-12months "outcomes of Vascular access" native and synthetic "in ESRD pediatrics
evaluation of short term "3-6months" and Mid term "6-12months" outcomes, patterns of complication in pediatrics with hemodialysis access(time frame one year after surgey) Primary (unassisted) patency The interval from the time of access creation until the first access thrombosis or any intervention to maintain or restore blood flow
Time frame: from 1october 2022to 28september 2023
2ry patency
To identify possible complications\&how to avoid Secondary (cumulative) patency "The time from access creation until access abandonment". Functional secondary patency" The interval from the first successful two-needle cannulation for haemodialysis treatment to access abandonment" possible complications include: 1. Stenosis 2. thrombosis 3. Infections
Time frame: from 1october 2022to 28september 2023
This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.